Skip to content
MarketScale
‹ Back to IndustriesHealthcare

On the Look-Out for Dry Eyes

For most of us, tears are associated solely with crying. In a moment of sadness or joy, we might shed a few tears–but otherwise, the curious water in our eyes is not something we typically worry about. Tears, as it turns out, are essential to maintaining eye health, helping to lubricate and nourish the eye…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

For most of us, tears are associated solely with crying. In a moment of sadness or joy, we might shed a few tears–but otherwise, the curious water in our eyes is not something we typically worry about. Tears, as it turns out, are essential to maintaining eye health, helping to lubricate and nourish the eye with every blink. Insufficient tearing, however, can result in dry eye, a chronic issue that is becoming increasingly prevalent.

While it is particularly common in older adults, dry eye affects anyone whose body either does not produce enough tears, or simply produces poor quality tears. This may seem like a minor annoyance, but dry eye can lead to some serious complications. For instance, the tears you produce help clear away dirt or harmful particles from your eyes, and without this cleansing process, eye infections gain a foothold. Even barring infection, a lack of tears can lead to abrasion on the surface of the cornea, vision problems and even corneal ulcers

The rise in popularity of LASIK surgery has brought the condition of dry eye into prevalence. For the best surgical outcome, it is important to be able to detect and control dry eye prior to the procedure. Luckily, there are several tests to help detect this condition.

The Schirmer Test is perhaps the most straight forward as it involves placing a very thin strip of paper under the lower eyelid in order to measure tear production. In what is known as the “tear breakup time” (TBUT) test, a small amount of dye is placed in the eye to monitor tear distribution. For those concerned about tests that directly interact with the eye’s surface, a keratometer can be used to analyze the tear film through imaging. And rounding out our list of the more common tests for dry eye is MMP-9 Testing, which involves taking a small sample of tears from the bottom lid. It is quick and painless, providing results in minutes as to whether a patient is ready for LASIK or if further treatment is needed.

Luckily, dry eye is very treatable. It all comes down to managing the quantity of tears produced or drained from the eyes. If too few tears are produced, over-the-counter artificial tear solutions are available, or your doctor may prescribe higher strength eye drops if a larger increase in tear production is necessary. If, however, tears are being drained too quickly through the tear ducts, silicone plugs can be used to block the ducts so that moisture is kept in the eye longer. Finally, dietary supplements such as flaxseed oil or Omega-3 fatty acids are also helpful in treating this condition.

While dry eye certainly is more common in those over the age of 65, it is something everyone should be aware of, as it is often caused by allergic reactions or even a medication you may be taking for an entirely different condition.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512